

## Author Index

- Allen, L.B., Teepe, A.G., Kehoe, M.J., Holland, C.S., McNamara, D.J. and Cook, P.D. Antiviral and cytotoxicity evaluation of 3-nitro-3-deazauridine, 259
- Aquino-de Jesus, M.J.C. and Griffith, B.P. Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing antiviral agents *in vivo*, 181
- Baron, S., see Lucia, H.L., 279
- Barrow, G.I., see Higgins, P.G., 49
- Bernstein, D.I., Kacica, M.A., McNeal, M.M., Schiff, G.M. and Ward, R.L. Local and systemic antibody response to rotavirus WC3 vaccine in adult volunteers, 293
- Borecky, L., Kontsek, P., Novák, M. and Lackovic, V. Human acid- and thermolabile  $\alpha$ -interferon-like substance: selective reactivity with a monoclonal antibody, 195
- Brown, G.A., see Field, H.J., 165
- Chan, V.F., see Hsiung, G.D., 239
- Cheetham, B.F., see Tymms, M.J., 37
- Choi, S.-S., Rasshofer, R. and Roggendorf, M. Inhibition of hepatitis delta virus RNA replication in primary woodchuck hepatocytes (Short Communication), 213
- Cook, P.D., see Allen, L.B., 259
- Cools, M., see Van Aerschot, A., 133
- Coppenhaver, D.H., see Lucia, H.L., 279
- Datema, R., see Tao, P.-Z., 269
- De Clercq, E. New acquisitions in the development of anti-HIV agents (Review Article), 1
- De Clercq, E., see Hosoya, M., 87
- De Clercq, E., see Van Aerschot, A., 133
- De Wilde, G.A., see Heijtink, R.A., 75
- Field, H.J. and Brown, G.A. Animal models for antiviral therapy (Mini Review), 165
- Fraser-Smith, E.B., see Freitas, V.R., 205
- Freitas, V.R., Fraser-Smith, E.B. and Matthews, T.R. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 *in vitro* and *in vivo*, 205
- Frost, H., see Higgins, P.G., 49
- Furukaza, H., see Yamamoto, N., 21
- Furuta, S., see Kiyosawa, K., 151
- Galbraith, A.W., see Higgins, P.G., 49
- Griffith, B.P., see Aquino-de Jesus, M.J.C., 181
- Hayata, T., see Kiyosawa, K., 151
- Hayden, F.G., see Sperber, S.J., 231
- Heijtink, R.A., De Wilde, G.A., Kruining, J., Smit-Leijen, M.B.L. and Schalm, S.W. Anti-pre-s(2) analysis after hepatitis B vaccination in haemodialysis patients, 75
- Herdewijn, P., see Van Aerschot, A., 133
- Higgins, P.G., Barrow, G.I., Galbraith, A.W., Frost, H. and Tyrrell, D.A.J. A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers (Short Communication), 49
- Holland, C.S., see Allen, L.B., 259
- Hosoya, M., Shigeta, S., Nakamura, K. and De Clercq, E. Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication *in vitro*, 87
- Hsiung, G.D. and Chan, V.F. Evaluation of new antiviral agents: II. The use of animal models, 239
- Hudson, J.B. Plant photosensitizers with antiviral properties (Review Article), 55
- Ito, Y., see Yamamoto, N., 21
- Janssen, G., see Van Aerschot, A., 133
- Johansson, N.G., see Tao, P.-Z., 269
- Kacica, M.A., see Bernstein, D.I., 293
- Kehoe, M.J., see Allen, L.B., 259
- Kiyosawa, K., Sodeyama, T., Nakano, Y., Yoda, H., Tanaka, E., Hayata, T., Tsuchiya, K., Yousof, M. and Furuta, S. Treatment of chronic non-A non-B hepatitis with human interferon B: a preliminary study, 151
- Kontsek, P., see Borecky, L., 195
- Kruining, J., see Heijtink, R.A., 75
- Lackovic, V., see Borecky, L., 195
- Linnane, A.W., see Tymms, M.J., 37
- Lucia, H.L., Coppenhaver, D.H. and Baron, S. Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon- $\alpha$ , the immunomodulator CL246,738 and ribavirin, 279
- Löfgren, B., Nordenfelt, E. and Öberg, B. Inhibition of RNA-and DNA-dependent duck

- hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs, 301
- Maeno, K., see Yamamoto, N., 21
- Matthews, T.R., see Freitas, V.R., 205
- McInnes, B., see Tymms, M.J., 37
- McNamara, D.J., see Allen, L.B., 259
- McNeal, M.M., see Bernstein, D.I., 293
- Middleton, Jr., E., see Spedding, G., 99
- Montgomery, J.A. Approaches to antiviral chemotherapy (Mini Review), 113
- Nakamura, K., see Hosoya, M., 87
- Nakano, Y., see Kiyosawa, K., 151
- Nishiyama, Y., see Yamamoto, N., 21
- Nordenfelt, E., see Löfgren, B., 301
- Novák, M., see Borecky, L., 195
- Öberg, B., see Tao, P.-Z., 269
- Öberg, B., see Löfgren, B., 301
- Okuno, T., see Shiraki, K., 311
- Public Health Service Animal Models Committee, see Spertzel, R.O., 223
- Rasshofer, R., see Choi, S-S., 213
- Ratty, A., see Spedding, G., 99
- Roggendorf, M., see Choi, S-S., 213
- Schalm, S.W., see Heijtink, R.A., 75
- Schiff, G.M., see Bernstein, D.I., 293
- Shigeta, S., see Hosoya, M., 87
- Shiraki, K., Okuno, T., Yamanishi, K. and Takahashi, M. Phosphonoacetic acid inhibits replication of human herpesvirus-6 (Short Communication), 311
- Smit-Leijs, M.B.L., see Heijtink, R.A., 75
- Sodeyama, T., see Kiyosawa, K., 151
- Spedding, G., Ratty, A. and Middleton, Jr., E. Inhibition of reverse transcriptases by flavonoids, 99
- Sperber, S.J. and Hayden, F.G. Protective effect of rhinovirus receptor blocking antibody in human fibroblast cells, 231
- Spertzel, R.O. and Public Health Service Animal Models Committee Animal models of human immunodeficiency virus infection (Mini Review), 223
- Stening, G., see Tao, P.-Z., 269
- Takahashi, M., see Shiraki, K., 311
- Tanaka, E., see Kiyosawa, K., 151
- Tao, P.-Z., Johansson, N.G., Stening, G., Öberg, B. and Datema, R. Inhibition of HIV-1 reverse transcriptase by 5'-triphosphates of 5-substituted uridine analogs, 269
- Teepe, A.G., see Allen, L.B., 259
- Tsuchiya, K., see Kiyosawa, K., 151
- Tymms, M.J., McInnes, B., Waine, G.J., Cheetham, B.F. and Linnane, A.W. Functional significance of amino acid residues within conserved hydrophilic regions in human interferons, 37
- Tyrrell, D.A.J., see Higgins, P.G., 49
- Van Aerschot, A., Herdewijn, P., Janssen, G., Cools, M. and De Clercq, E. Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-fluoro-deoxyadenosine, 133
- Waine, G.J., see Tymms, M.J., 37
- Ward, R.L., see Bernstein, D.I., 293
- Yamamoto, N., Furukaza, H., Ito, Y., Yoshida, S., Maeno, K. and Nishiyama, Y. Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds, 21
- Yamanishi, K., see Shiraki, K., 311
- Yoda, H., see Kiyosawa, K., 151
- Yoshida, S., see Yamamoto, N., 21
- Yousof, M., see Kiyosawa, K., 151

## Subject Index

- AIDS**, Cytomegalovirus infection, Immunocompromised pig, 9-(1-3-Dihydroxy-2-propoxymethyl)guanine, Bone marrow transplant, Antiviral testing, 181
- Acridone alkaloid**, Citrusinine-I, Herpes simplex virus, Human cytomegalovirus, 21
- Acyclovir**, Hepatitis delta virus (HDV), Replication, Primary hepatocyte culture, Ribavirin, Sumarin,  $\alpha$ -Amanitin, 213
- Adenosylhomocysteine hydrolase**, S, 3'-Fluoro-3'-deoxyribonucleoside, 3'-Fluoro-3'-deoxyadenosine, Vaccinia virus, Picorna virus, Reovirus, 133
- Alkaloid**, Photosensitizer, Phytochemical, Thiophene, Polyacetylene, Furyl compound, Furocoumarin, Furanochromone,  $\beta$ -carboline, 55
- $\alpha$ -Amanitin**, Hepatitis delta virus (HDV), Replication, Primary hepatocyte culture, Ribavirin, Sumarin, Acyclovir, 213
- Amentoflavone**, Reverse transcriptase, Flavonoid Kinetics, Quercetin, Scutellarein, 99
- Animal model**, Inhibitor, Virus infection, HSV, HIV, 165
- Animal model**, HIV-infection, Rodent, Rabbit, Primate, 223
- Animal model**, Guinea pig, Mice, Herpesvirus infection, Antiviral agent testing in vivo, 239
- Anti-RNA virus activity**, 3-Nitro-3-deazauridine, Ribavirin, 259
- Anti-pre-S(2)**, Hepatitis B vaccination, Dialysis, EIA, Western blot, 75
- Antimetabolite**, Antiviral development, Carbocyclic nucleoside analog, Drug metabolism, Uridine-pyrimidine antimetabolite, 113
- Antiproliferative activity**, Interferon- $\alpha$ , In vitro mutagenesis, Antiviral activity, 37
- Antiviral activity**, Interferon- $\alpha$ , In vitro mutagenesis, Antiproliferative activity, 37
- Antiviral development**, Carbocyclic nucleoside analog, Drug metabolism, Antimetabolite, Uridine-pyrimidine antimetabolite, 113
- Antiviral testing**, Cytomegalovirus infection, Immunocompromised guinea pig, 9-(1-3-Dihydroxy-2-propoxymethyl)guanine, AIDS, Bone marrow transplant, 181
- Antiviral agent testing in vivo**, Animal model, Guinea pig, Mice, Herpesvirus infection, 239
- Antiviral therapy**, Arenaviral infection, Pichinde virus, Strain 13 guinea pig, Interferon, Immunomodulator, CL246,738, 279
- Antiviral**, Rhinovirus, Receptor, Monoclonal antibody, 231
- Arenaviral infection**, Pichinde virus, Strain 13 guinea pig, Interferon, Immunomodulator, Antiviral therapy, CL246,738, 279
- Autoimmune disease**, Interferon-like substance, Monoclonal antibody, Polyclonal antibody, 195
- 6-Azuridine**, Measles, SSPE, Pyrazofurin, 3-Deazaguanine, Ribavirin, 87
- Bone marrow transplant**, Cytomegalovirus infection, Immunocompromised guinea pig, 9-(1-3-Dihydroxy-2-propoxymethyl)guanine, AIDS, Antiviral testing, 181
- CGP 19835 A (MTP-PE)**, Influenza A virus, Human volunteer, 49
- CL246,738**, Arenaviral infection, Pichinde virus, Strain 13 guinea pig, Interferon, Immunomodulator, Antiviral therapy, 279
- carboline, Photosensitizer, Phytochemical, Thiophene, Polyacetylene, Furyl compound, Furocoumarin, Furanochromone, Alkaloid, 55
- Carbocyclic nucleoside analog**, Antiviral development, Drug metabolism, Antimetabolite, Uridine-pyrimidine antimetabolite, 113
- Chemotherapy**, Human immunodeficiency virus, Reverse transcriptase, Nucleoside analog, 269
- Chronic non-A non-B hepatitis**, Chronic type B hepatitis, Human interferon-B, 151
- Chronic type B hepatitis**, Chronic non-A non-B hepatitis, Human interferon-B, 151
- Citrusinine-I**, Acridone alkaloid, Herpes simplex virus, Human cytomegalovirus, 21
- Combination study**, Cytomegalovirus, human, murine, HSV-2, Ganciclovir, DHPG, Foscarnet, PFA, 205
- Cytomegalovirus infection**, Immunocompromised guinea pig, 9-(1-3-Dihydroxy-2-propoxymethyl)guanine, AIDS, Bone marrow transplant, Antiviral testing, 181
- Cytomegalovirus**, human, murine, HSV-2, Ganciclovir, DHPG, Foscarnet, PFA, Combination study, 205
- DHPG**, Foscarnet, Cytomegalovirus, human, murine, HSV-2, Ganciclovir, PFA, Combination study, 205
- DNA polymerase**, Human herpesvirus-6, Phosphonoacetic acid, 311

- DNA-dependent DNA polymerase**, Duck hepatitis B virus, Reverse transcriptase, Pyrophosphate analog, 2',3'-Dideoxynucleoside 5'-triphosphate analog, 301
- Deazaguanine**, Measles, SSPE, Pyrazofurin, 6-Azauridine, Ribavirin, 87 Dialysis, Hepatitis B vaccination, Anti-pre-S(2), EIA, Western blot, 75
- 9-(1,3-Dihydroxy-2-propoxymethyl)guanine**, Cytomegalovirus infection, Immunocompromised guinea pig, AIDS, Bone marrow transplant, Antiviral testing, 181
- 2',3'-Dideoxynucleoside 5'-triphosphate analog**, Duck hepatitis B virus, DNA-dependent DNA polymerase, Reverse transcriptase, Pyrophosphate analog, 301
- Drug metabolism**, Antiviral development, Carbocyclic nucleoside analog, Antimetabolite, Uridine-pyrimidine antimetabolite, 113
- Duck hepatitis B virus**, DNA-dependent DNA polymerase, Reverse transcriptase, Pyrophosphate analog, 2',3'-Dideoxynucleoside 5'-triphosphate analog, 301
- EIA**, Hepatitis B vaccination, Dialysis, Anti-pre-S(2), Western blot, 75
- Flavonoid**, Reverse transcriptase, Kinetics, Quercetin, Amentoflavone, Scutellarein, 99
- 3'-Fluoro-3'-deoxyribonucleoside**, 3'-Fluoro-3'-deoxyadenosine, Adenosylhomocysteine hydrolase, S, Vaccinia virus, Picorna virus, Reovirus, 133
- 3'-Fluoro-3'-deoxyadenosine**, 3'-Fluoro-3'-deoxyribonucleoside, Adenosylhomocysteine hydrolase, S, Vaccinia virus, Picorna virus, Reovirus, 133
- Furanochromone**, Photosensitizer, Phytochemical, Thiophene, Polyacetylene, Furyl compound, Furocoumarin, Alkaloid,  $\beta$ -carboline, 55
- Furocoumarin**, Photosensitizer, Phytochemical, Thiophene, Polyacetylene, Furyl compound, Furanochromone, Alkaloid,  $\beta$ -carboline, 55
- Furyl compound**, Photosensitizer, Phytochemical, Thiophene, Polyacetylene, Furocoumarin, Furanochromone, Alkaloid,  $\beta$ -carboline, 55
- Ganciclovir**, Cytomegalovirus, Human, Murine, HSV-2, DHPG, Foscarnet, PFA, Combination study, 205
- Guinea pig**, Animal model, Mice, Herpesvirus infection, Antiviral agent testing in vivo, 239
- HIV**, Animal model, Inhibitor, Virus infection, HSV, 165
- HIV-infection**, Animal model, Rodent, Rabbit, Primate, 223
- HSV**, Animal model, Inhibitor, Virus infection, HIV, 165
- HSV-2**, Cytomegalovirus, human, murine, Ganciclovir, DHPG, Foscarnet, PFA, Combination study, 205
- Hepatitis B vaccination**, Dialysis, Anti-pre-S(2), EIA, Western blot, 75
- Hepatitis delta virus (HDV)**, Replication, Primary hepatocyte culture, Ribavirin, Suramin, Acyclovir,  $\alpha$ -Amanitin, 213
- Herpes simplex virus**, Citrusinine-I, Acridone alkaloid, Human cytomegalovirus, 21
- Herpesvirus infection**, Animal model, Guinea pig, Mice, Antiviral agent testing in vivo, 239
- Human cytomegalovirus**, Citrusinine-I, Acridone alkaloid, Herpes simplex virus, 21
- Human herpesvirus-6**, Phosphonoacetic acid, DNA polymerase, 311
- Human immunodeficiency virus**, Reverse transcriptase, Nucleoside analog, Chemotherapy, 269
- Human interferon- $\beta$** , Chronic non-A non-B hepatitis, Chronic type B hepatitis, 151
- Human volunteer**, CGP 19835 A (MTP-PE), Influenza A virus, 49
- Immune response**, Rotavirus vaccine, Stool rotavirus IgA, 293
- Immunocompromised guinea pig**, Cytomegalovirus infection, 9-(1,3-Dihydroxy-2-propoxymethyl)guanine, AIDS, Bone marrow transplant, Antiviral testing, 181
- Immunomodulator**, Arenaviral infection, Pichinde virus, Strain 13 guinea pig, Interferon, Antiviral therapy, CL246,738, 279
- In vitro mutagenesis**, Interferon- $\alpha$ , Antiviral activity, Antiproliferative activity, 37
- Influenza A virus**, CGP 19835 A (MTP-PE), Human volunteer, 49
- Inhibitor**, Animal model, Virus infection, HSV, HIV, 165
- Interferon- $\alpha$** , In vitro mutagenesis, Antiviral activity, Antiproliferative activity, 37
- Interferon-like substance**, Monoclonal antibody, Polyclonal antibody, Autoimmune disease, 195
- Interferon**, Arenaviral infection, Pichinde virus, Strain 13 guinea pig, Immunomodulator, Antiviral therapy, CL246,738, 279

- Kinetics**, Reverse transcriptase, Flavonoid, Quercetin, Amentoflavone, Scutellarein, 99
- Measles**, SSPE, Pyrazofurin, 3-Deazaguanine, 6-Azauridine, Ribavirin, 87
- Mice**, Animal model, Guinea pig, Herpesvirus infection, Antiviral agent testing in vivo, 239
- Monoclonal antibody**, Interferon-like substance, Polyclonal antibody, Autoimmune disease, 195
- Monoclonal antibody**, Rhinovirus, Antiviral, Receptor, 231
- 3-Nitro-3-deazauridine**, Anti-RNA virus activity, Ribavirin, 259
- Nucleoside analog**, Human immunodeficiency virus, Reverse transcriptase, Chemotherapy, 269
- PFA**, Cytomegalovirus, human, murine, HSV-2, Ganciclovir, DHPG, Foscarnet, Combination study, 205
- Phosphonacetic acid**, Human herpesvirus-6, DNA polymerase, 311
- Photosensitizer**, Phytochemical, Thiophene, Polyacetylene, Furyl compound, Furocoumarin, Furanochromone, Alkaloid,  $\beta$ -carboline, 55
- Phytochemical**, Photosensitizer, Thiophene, Polyacetylene, Furyl compound, Furocoumarin, Furanochromone, Alkaloid,  $\beta$ -carboline, 55
- Pichinde virus**, Arenaviral infection, Strain 13 guinea pig, Interferon, Immunomodulator, Antiviral therapy, CL246,738, 279
- Picornavirus**, 3'-Fluoro-3'-deoxyribonucleoside, 3'-Fluoro-3'-deoxyadenosine, Adenosylhomocysteine hydrolase, S, Vaccinia virus, reovirus, 133
- Polyacetylene**, Photosensitizer, Phytochemical, Thiophene, Furyl compound, Furocoumarin, Furanochromone, Alkaloid,  $\beta$ -carboline, 55
- Polyclonal antibody**, Interferon-like substance, Monoclonal antibody, Autoimmune disease, 195
- Primary hepatocyte culture**, Hepatitis delta virus (HDV), Replication, Ribavirin, Suramin, Acyclovir,  $\alpha$ -Amanitin, 213
- Primate**, HIV-infection, Animal model, Rodent, Rabbit, 223
- Pyrazofurin**, Measles, SSPE, 3-Deazaguanine, 6-Azauridine, Ribavirin, 87
- Pyrophosphate analog**, Duck hepatitis B virus, DNA-dependent DNA polymerase, Reverse transcriptase, 2',3'-Dideoxynucleoside 5'-triphosphate analog, 301
- Quercetin**, Reverse transcriptase, Flavonoid, Kinetics, Amentoflavone, Scutellarein, 99
- Rabbit**, HIV-infection, Animal model, Rodent, Primate, 223
- Receptor**, Rhinovirus, Antiviral, Monoclonal antibody, 231
- Reovirus**, 3'-Fluoro-3'-deoxyribonucleoside, 3'-Fluoro-3'-deoxyadenosine, Adenosylhomocysteine hydrolase, S, Vaccinia virus, Picorna virus, 133
- Replication**, Hepatitis delta virus (HDV), Primary hepatocyte culture, Ribavirin, Suramin, Acyclovir,  $\alpha$ -Amanitin, 213
- Reverse transcriptase**, Flavonoid, Kinetics, Quercetin, Amentoflavone, Scutellarein, 99
- Reverse transcriptase**, Human immunodeficiency virus, Nucleoside analog, Chemotherapy, 269
- Reverse transcriptase**, Duck hepatitis B virus, DNA-dependent DNA polymerase, Pyrophosphate analog, 2',3'-Dideoxynucleoside 5'-triphosphate analog, 301
- Rhinovirus**, Antiviral, Receptor, Monoclonal antibody, 231
- Ribavirin**, Measles, SSPE, Pyrazofurin, 3-Deazaguanine, 6-Azauridine, 87
- Ribavirin**, Hepatitis delta virus (HDV), Replication, Primary hepatocyte culture, Suramin, Acyclovir,  $\alpha$ -Amanitin, 213
- Ribavirin**, Anti-RNA virus activity, 3-Nitro-3-deazauridine, 259
- Rodent**, HIV-infection, Animal model, Rabbit, Primate, 223
- Rotavirus vaccine**, Immune response, Stool rotavirus IgA, 293
- SSPE**, Measles, Pyrazofurin, 3-Deazaguanine, 6-Azauridine, Ribavirin, 87
- Scutellarein**, Reverse transcriptase, Flavonoid, Kinetics, Quercetin, Amentoflavone, 99
- Stool rotavirus IgA**, Rotavirus vaccine, Immune response, 293
- Strain 13 guinea pig**, Arenaviral infection, Pichinde virus, Interferon, Immunomodulator, Antiviral therapy, CL246,738, 279
- Suramin**, Hepatitis delta virus (HDV), Replication, Primary hepatocyte culture, Ribavirin, Acyclovir,  $\alpha$ -Amanitin, 213
- Thiophene**, Photosensitizer, Phytochemical, Polyacetylene, Furyl compound, Furocoumarin, Furanochromone, Alkaloid,  $\beta$ -carboline, 55
- Uridine-pyrimidine antimetabolite**, Antiviral development, Carbocyclic nucleoside analog, Drug metabolism, Antimetabolite, 113

**Vaccinia virus**, 3'-Fluoro-3'-deoxyribonucleoside,  
3'-Fluoro-3'-deoxyadenosine, Adenosylhomocysteine hydrolase, S, Picorna virus, Reovirus,  
133

**Virus infection**, Animal model, Inhibitor, HSV,  
HIV, 165

**Western blot**, Hepatitis B vaccination, Dialysis,  
Anti-pre-S(2), EIA, 75

